Cargando…
Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
Although pathological cardiac hypertrophy represents a leading cause of morbidity and mortality worldwide, our understanding of the molecular mechanisms underlying this disease is still poor. Here, we demonstrate that suppressor of IKKɛ (SIKE), a negative regulator of the interferon pathway, attenua...
Autores principales: | Deng, Ke-Qiong, Wang, Aibing, Ji, Yan-Xiao, Zhang, Xiao-Jing, Fang, Jing, Zhang, Yan, Zhang, Peng, Jiang, Xi, Gao, Lu, Zhu, Xue-Yong, Zhao, Yichao, Gao, Lingchen, Yang, Qinglin, Zhu, Xue-Hai, Wei, Xiang, Pu, Jun, Li, Hongliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895691/ https://www.ncbi.nlm.nih.gov/pubmed/27249321 http://dx.doi.org/10.1038/ncomms11432 |
Ejemplares similares
-
Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2023) -
The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
por: Ji, Yan-Xiao, et al.
Publicado: (2016) -
NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity
por: Zhang, Xin, et al.
Publicado: (2020) -
Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy
por: Gao, Maomao, et al.
Publicado: (2020) -
Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway
por: Liao, Hai-han, et al.
Publicado: (2019)